Related Experiment Video
Updated: Jul 18, 2026
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Ba/F3 cells and their use in kinase drug discovery
Markus Warmuth1, Sungjoon Kim, Xiang-ju Gu
1Kinase Platform and Department of Lead Discovery, Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, USA. mwarmuth@gnf.org
Purpose Of Review:
Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics. The discovery of a large number of cancer-associated mutations in the kinome, and the progress in developing specific small-molecule kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems.
Recent Findings:
Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-molecule kinase inhibitors to block kinase activity. Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compound profiling. Further, several published approaches show promise in predicting resistance to small-molecule kinase inhibitors elicited by point mutations interfering with inhibitor binding.
Summary:
Ba/F3 cells are an increasingly popular tool in kinase drug discovery. The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compound libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clinical resistance will greatly facilitate developments in this field.
Insights
Ba/F3 cells are a valuable tool for kinase drug discovery, enabling the assessment of oncogenic kinase activity and inhibitor efficacy. This model system aids in predicting drug resistance and advancing targeted cancer therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Protein kinases are key targets for molecularly-targeted cancer chemotherapeutics due to their role as dominant oncogenes.
- The identification of numerous cancer-associated mutations in the kinome necessitates robust kinase activity-dependent cellular assay systems.
- Developing specific small-molecule kinase inhibitors requires accurate and efficient assay platforms.
Purpose of the Study:
- To highlight the utility of Ba/F3 cells as a model system for evaluating kinase oncogenes and small-molecule kinase inhibitors.
- To discuss the adaptation of Ba/F3 cells for high-throughput screening and compound profiling.
- To explore the potential of Ba/F3 cells in predicting resistance to kinase inhibitors.
Main Methods:
- Utilizing Ba/F3 cells, a murine interleukin-3 dependent pro-B cell line, to assess kinase oncogene potency and downstream signaling.
- Adapting Ba/F3 cells to high-throughput assay formats for efficient compound profiling.
- Employing published approaches with Ba/F3 cells to predict resistance to small-molecule kinase inhibitors.
Main Results:
- Ba/F3 cells are increasingly utilized for assessing kinase oncogene activity and inhibitor potency.
- High-throughput screening formats using Ba/F3 cells facilitate compound profiling.
- Published methods demonstrate Ba/F3 cells' promise in predicting inhibitor resistance caused by specific mutations.
Conclusions:
- Ba/F3 cells are a popular and effective tool in kinase drug discovery.
- The system allows for testing the transforming capacity of novel kinase mutations.
- Ba/F3 cells facilitate high-throughput profiling of drug candidates and prediction of clinical resistance, accelerating therapeutic development.
